Children with high adherence to ADHD medication methylphenidate at greater risk of being prescribed antidepressants
March 27, 2019Research and Development ADHA, mental health, methylphenidate, mph, psychiatric disorders
Children who were treated with methylphenidate-based medications (i.e. Ritalin) for conditions such as ADHD were at significantly greater risk of …
Novartis’ new MS drug to cost $88,000 a year
March 27, 2019Research and Development, Sales and Marketing FDA, MS, Novartis, Novartis pharmaceuticals, multiple sclerosis
Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will …
Purdue Pharma settle Oklahoma lawsuit for $270 million
March 26, 2019Research and Development Oklahoma, OxyContin, Purdue Pharma, opioid crisis, oxycodone
OxyContin drugmaker Purdue Pharma has agreed to pay nearly $270 million to the state of Oklahoma, in order to settle …
Novo Nordisk’s oral semaglutide outclasses Januvia with new data in type 2 diabetes
March 26, 2019Manufacturing and Production, Research and Development Novo Nordisk, Ozempic, diabetes, pharma, type 2 diabetes
Novo Nordisk has revealed new dose-specific Phase 3a data for its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide, indicating that the …
Aimmune’s peanut allergy therapy closes in on approval with promising Phase 3 data
March 26, 2019Manufacturing and Production, Research and Development AR101, Aimmune, allergy, pharma
Aimmune Therapeutics is gearing up for regulatory review of its investigational food allergy therapy AR101 following the release of new …
Sackler Trust halts donations in UK
March 26, 2019Manufacturing and Production Sackler Trust, arts, culture, donations, funding, gallery, sackler
The Sackler Trust has announced it is suspending all new donations in the UK amid negative publicity linking the family’s …
Sanofi may airlift flu vaccines into UK after Brexit
March 26, 2019Manufacturing and Production EU, France, Sanofi, UK, brexit, channel tunnel, vaccines
French firm Sanofi would airlift flu vaccines into the UK in the case of a highly disruptive exit from the …
Google accused of profiting from misleading dementia supplement ads
March 26, 2019Manufacturing and Production Alzheimer's, dementia, google, pseudomedicine, search engines, tech
Google has been accused of profiting from false hope after running adverts for unproven dementia treatments which can cost as …
Conducting internal investigations within a pharmaceutical business
March 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Reed Smith, feature, internal investigations, pharma
Though often necessary, internal investigations are seldom smooth or easy. Rosanne Kay, Partner at law firm Reed Smith, outlines a …
Sanofi and Lexicon’s Zynquista denied type 1 diabetes approval by FDA complete response letter
March 25, 2019Sales and Marketing Zynquista. FDA, diabetes, pharma
Sanofi and Lexicon’s Zynquista (sotagliflozin) has hit a hurdle on its way to US approval for the treatment of type …
NICE recommend Takeda’s lymphoma treatment Adcetris
March 25, 2019Sales and Marketing Cancer, NICE, Takeda, UK, lymphoma, oncology, recommendation
Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma …
Africa’s legal cannabis market could generate $7.1 billion each year by 2023
March 25, 2019Sales and Marketing Africa, UN, cannabis, medicnial cannabis, prohibition partners
Africa’s legal cannabis market could generate more than $7.1 billion each year by 2023, according to a report from market …
AZ’s diabetes drug Forxiga secures EU approval for adjunctive use in type 1 patients
March 25, 2019Sales and Marketing AstraZeneca, Forxiga, diabetes, pharma
AstraZeneca has revealed that its sodium-glucose co-transporter 2 (SGLT2) inhibitor Forxiga (dapagliflozin) has secured approval from the European Commission for …
Advertising Standards Authority tells therapists to stop marketing ‘autism cure’
March 25, 2019Sales and Marketing ASA, CEASE therapy, advertising standards authority, anti-vaccines, autism, vaccines
The Advertising Standards Authority (ASA) has told British therapists to stop marketing a sham ‘cure’ for autism. The regulator told …
FDA authorises Jazz Pharma’s sleep disorder therapy Sunosi
March 22, 2019Medical Communications, Sales and Marketing FDA, jazz pharmaceuticals, pharma, sleep apnoea
Jazz Pharmaceuticals has announced that its dopamine and norepinephrine reuptake inhibitor (DNRI) Sunosi (solriamfetol) has been approved by the FDA …
Top Ten most popular articles on Pharmafile.com this week!
March 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Biogen, Eisai, FDA, Merck, NICE, Pfizer, Roche, Sandoz
This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on …
Specialists petition FDA over opioid approval process
March 22, 2019Medical Communications FDA, approval process, opioid crisis, opioids, painkillers
FDA officials have called on the federal agency to halt the approval of new narcotic painkillers. Dr Sidney Wolfe, a …
Tate art galleries will not accept donations from Sacklers
March 22, 2019Medical Communications OxyContin, Purdue Pharma, Sacklers, Tate, art galleries, opioid crisis
The Tate network of art galleries has said it will no longer accept gifts from the notorious Sackler family, the …
Department of Veteran Affairs to offer Janssen’s esketamine to veterans with depression
March 21, 2019Medical Communications Jannsen, Spravato, VA, depression, esketamine, military, veteran affairs
The United States Department of Veteran Affairs (VA), the federal agency responsible for providing healthcare services to military veterans, is …
Breathing life into COPD research
March 21, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COPD, GSK, feature
Alison Hollands, Vice President, Respiratory, UK Pharmaceuticals at GlaxoSmithKline, addresses the importance of implementing the latest approaches to treating COPD …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
